<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37085289</PMID><DateCompleted><Year>2023</Year><Month>06</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-2060</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Annals of the rheumatic diseases</Title><ISOAbbreviation>Ann Rheum Dis</ISOAbbreviation></Journal><ArticleTitle>Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes.</ArticleTitle><Pagination><StartPage>927</StartPage><EndPage>936</EndPage><MedlinePgn>927-936</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/ard-2022-223808</ELocationID><Abstract><AbstractText Label="OBJECTIVES">A novel longitudinal clustering technique was applied to comprehensive autoantibody data from a large, well-characterised, multinational inception systemic lupus erythematosus (SLE) cohort to determine profiles predictive of clinical outcomes.</AbstractText><AbstractText Label="METHODS">Demographic, clinical and serological data from 805 patients with SLE obtained within 15 months of diagnosis and at 3-year and 5-year follow-up were included. For each visit, sera were assessed for 29 antinuclear antibodies (ANA) immunofluorescence patterns and 20 autoantibodies. K-means clustering on principal component analysis-transformed longitudinal autoantibody profiles identified discrete phenotypic clusters. One-way analysis of variance compared cluster enrolment demographics and clinical outcomes at 10-year follow-up. Cox proportional hazards model estimated the HR for survival adjusting for age of disease onset.</AbstractText><AbstractText Label="RESULTS">Cluster 1 (n=137, high frequency of anti-Smith, anti-U1RNP, AC-5 (large nuclear speckled pattern) and high ANA titres) had the highest cumulative disease activity and immunosuppressants/biologics use at year 10. Cluster 2 (n=376, low anti-double stranded DNA (dsDNA) and ANA titres) had the lowest disease activity, frequency of lupus nephritis and immunosuppressants/biologics use. Cluster 3 (n=80, highest frequency of all five antiphospholipid antibodies) had the highest frequency of seizures and hypocomplementaemia. Cluster 4 (n=212) also had high disease activity and was characterised by multiple autoantibody reactivity including to antihistone, anti-dsDNA, antiribosomal P, anti-Sj&#xf6;gren syndrome antigen A or Ro60, anti-Sj&#xf6;gren syndrome antigen B or La, anti-Ro52/Tripartite Motif Protein 21, antiproliferating cell nuclear antigen and anticentromere B). Clusters 1 (adjusted HR 2.60 (95% CI 1.12 to 6.05), p=0.03) and 3 (adjusted HR 2.87 (95% CI 1.22 to 6.74), p=0.02) had lower survival compared with cluster 2.</AbstractText><AbstractText Label="CONCLUSION">Four discrete SLE patient longitudinal autoantibody clusters were predictive of long-term disease activity, organ involvement, treatment requirements and mortality risk.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>May Yee</ForeName><Initials>MY</Initials><Identifier Source="ORCID">0000-0003-3760-2737</Identifier><AffiliationInfo><Affiliation>Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada may.choi@ucalgary.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Irene</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clarke</LastName><ForeName>Ann Elaine</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fritzler</LastName><ForeName>Marvin J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0003-1652-6608</Identifier><AffiliationInfo><Affiliation>Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buhler</LastName><ForeName>Katherine A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Medicine, University of Calgary Cumming School of Medicine, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urowitz</LastName><ForeName>Murray</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7506-9166</Identifier><AffiliationInfo><Affiliation>Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanly</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Medicine and Department of Pathology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>St-Pierre</LastName><ForeName>Yvan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Medicine, Research Institute of the McGill University Health Center, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gordon</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rheumatology Research Group, Institute of Inflammation and Ageing, College of Medical and Dental Sciences, Birmingham University Medical School, Birmingham, West Midlands, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bae</LastName><ForeName>Sang-Cheol</ForeName><Initials>SC</Initials><Identifier Source="ORCID">0000-0003-4658-1093</Identifier><AffiliationInfo><Affiliation>Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Hanyang University Institute for Rheumatology and Hanyang University Institute of Bioscience and Biotechnology, Seoul, The Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romero-Diaz</LastName><ForeName>Juanita</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Immunology and Rheumatology, Instituto Nacional de Ciencias M&#xe9;dicas y Nutrici&#xf3;n, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Guerrero</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Mount Sinai Hospital and University Health Network, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bernatsky</LastName><ForeName>Sasha</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9515-2802</Identifier><AffiliationInfo><Affiliation>Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Daniel J</ForeName><Initials>DJ</Initials><Identifier Source="ORCID">0000-0002-2502-1372</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Isenberg</LastName><ForeName>David Alan</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0001-9514-2455</Identifier><AffiliationInfo><Affiliation>Centre for Rheumatology, Department of Medicine, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rahman</LastName><ForeName>Anisur</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2346-4484</Identifier><AffiliationInfo><Affiliation>Centre for Rheumatology, Department of Medicine, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merrill</LastName><ForeName>Joan T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fortin</LastName><ForeName>Paul R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0002-7278-2596</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, CHU de Qu&#xe9;bec - Universit&#xe9; Laval, Quebec City, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gladman</LastName><ForeName>Dafna D</ForeName><Initials>DD</Initials><Identifier Source="ORCID">0000-0002-9074-0592</Identifier><AffiliationInfo><Affiliation>Center for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital, University of Toronto, Lupus Clinic, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bruce</LastName><ForeName>Ian N</ForeName><Initials>IN</Initials><AffiliationInfo><Affiliation>Epidemiology Unit, University of Manchester, Manchester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petri</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-1441-5373</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ginzler</LastName><ForeName>Ellen M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Department of Medicine, SUNY Downstate Medical Center, Brooklyn, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dooley</LastName><ForeName>Mary Anne</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramsey-Goldman</LastName><ForeName>Rosalind</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Northwestern University and Feinberg School of Medicine, Chicago, Illinois, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manzi</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medicine, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf6;nsen</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Sciences, Lund University, Lund, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alarc&#xf3;n</LastName><ForeName>Graciela S</ForeName><Initials>GS</Initials><Identifier Source="ORCID">0000-0001-5190-9175</Identifier><AffiliationInfo><Affiliation>Department of Medicine, The University of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Vollenhoven</LastName><ForeName>Ronald F</ForeName><Initials>RF</Initials><Identifier Source="ORCID">0000-0001-6438-8663</Identifier><AffiliationInfo><Affiliation>Rheumatology &amp; Immunology Center, University of Amsterdam, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aranow</LastName><ForeName>Cynthia</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-9299-0053</Identifier><AffiliationInfo><Affiliation>Division of Autoimmune and Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mackay</LastName><ForeName>Meggan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Autoimmune and Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruiz-Irastorza</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-7788-1043</Identifier><AffiliationInfo><Affiliation>Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Inanc</LastName><ForeName>Murat</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-6376-5583</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalunian</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Allergy and Immunology, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jacobsen</LastName><ForeName>S&#xf8;ren</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peschken</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kamen</LastName><ForeName>Diane L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Division of Rheumatology &amp; Immunology, Medical University of South Carolina, Charleston, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Askanase</LastName><ForeName>Anca</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital for Joint Diseases, New York University, Seligman Centre for Advanced Therapeutics, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buyon</LastName><ForeName>Jill P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, New York University School of Medicine, New York, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sontag</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costenbader</LastName><ForeName>Karen H</ForeName><Initials>KH</Initials><Identifier Source="ORCID">0000-0002-8972-9388</Identifier><AffiliationInfo><Affiliation>Department of Medicine, Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Acronym>VAC_</Acronym><Agency>Versus Arthritis</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>DH_</Acronym><Agency>Department of Health</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>UL1 TR000150</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025741</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AR002128</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P60 AR064464</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P60 AR048098</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AR046588</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AR002213</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AR066109</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Rheum Dis</MedlineTA><NlmUniqueID>0372355</NlmUniqueID><ISSNLinking>0003-4967</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000974">Antibodies, Antinuclear</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-49-2</RegistryNumber><NameOfSubstance UI="D004247">DNA</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="Y">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000974" MajorTopicYN="N">Antibodies, Antinuclear</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004247" MajorTopicYN="N">DNA</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">autoantibodies</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>Competing interests: MYC has received consulting fees from Janssen, AstraZeneca, Mallinckrodt Pharmaceuticals and MitogenDx. AEC has received consulting fees, speaking fees and/or honoraria from AstraZeneca, Bristol Myers Squibb and GlaxoSmithKline (&lt;US$10 000 each) and research support from GlaxoSmithKline. MJF is Director of Mitogen Diagnostics (Calgary, Alberta, Canada) and a consultant to Werfen International (San Diego, California, USA; Barcelona, Spain), Aesku Group (Wendelsheim, Germany) and Alexion Canada (&lt;US$10 000). CG has received consulting fees, speaking fees and/or honoraria from Eli Lilly, UCB, GlaxoSmithKline, Merck Serono and BMS (&lt;US$10 000 each) and grants from UCB. Grants from UCB were not to CG but to Sandwell and West Birmingham Hospitals NHS Trust. DDG received consulting fees, speaking fees and/or honoraria from GlaxoSmithKline (&lt;US$10 000). INB has received consulting fees, speaking fees and/or honoraria from Eli Lilly, UCB, Roche, Merck Serono, MedImmune (&lt;US$10 000 each) and grants from UCB, Genzyme Sanofi and GlaxoSmithKline. EMG has paid consultation with investment analysts Guidepoint Global Gerson Lerman Group. KK has received grants from UCB, Human Genome Sciences/GlaxoSmithKline, Takeda, Ablynx, Bristol Myers Squibb, Pfizer and Kyowa Hakko Kirin, and has received consulting fees from Exagen Diagnostics, Genentech, Eli Lilly, Bristol Myers Squibb and Anthera (&lt;US$10 000 each). KHC has consulted for or collaborated on research projects with Janssen, GlaxoSmithKline, Gilead, Exagen Diagnostics, Lilly, Merck, AstraZeneca, Amgen and Neutrolis (&lt;US$10 000 each). The remainder of the authors have no disclosures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>4</Month><Day>22</Day><Hour>10</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>4</Month><Day>21</Day><Hour>21</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37085289</ArticleId><ArticleId IdType="doi">10.1136/ard-2022-223808</ArticleId><ArticleId IdType="pii">ard-2022-223808</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>